Alerts will be sent to your verified email
Verify EmailIPCALAB
Ipca Laboratories
|
Ajanta Pharma
|
Gland Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
44.0 . | 76.0 . | 371.0 . |
Number of ANDA's Approved By USFDA
|
31.0 . | 55.0 . | 318.0 . |
Domestic Sales Growth - YoY
|
8.3 % | 7.5 % | n/a |
US DMF Filings
|
55.0 . | n/a | 68.0 . |
R&D as a % of Total Sales
|
3.12 % | 4.0 % | 4.9 % |
Financials
|
|||
5 yr Average ROE
|
13.55 % | 21.63 % | 12.02 % |
5yr average Equity Multiplier
|
1.52 | 1.32 | 1.15 |
5yr Average Asset Turnover Ratio
|
0.76 | 0.84 | 0.51 |
5yr Avg Net Profit Margin
|
11.88 % | 19.77 % | 20.79 % |
Price to Book
|
5.3 | 8.88 | 3.56 |
P/E
|
49.94 | 36.2 | 46.68 |
5yr Avg Cash Conversion Cycle
|
54.3 Days | -102.34 Days | 69.81 Days |
Inventory Days
|
102.83 Days | 55.16 Days | 118.26 Days |
Days Receivable
|
72.68 Days | 49.8 Days | 99.92 Days |
Days Payable
|
111.38 Days | 195.69 Days | 107.43 Days |
5yr Average Interest Coverage Ratio
|
50.79 | 108.5 | 183.05 |
5yr Avg ROCE
|
17.31 % | 27.48 % | 16.55 % |
5yr Avg Operating Profit Margin
|
19.8 % | 27.65 % | 29.26 % |
5 yr average Debt to Equity
|
0.17 | 0.0 | 0.01 |
5yr CAGR Net Profit
|
-8.34 % | 7.08 % | -6.87 % |
5yr Average Return on Assets
|
9.41 % | 16.51 % | 10.65 % |
Shareholdings
|
|||
Promoter Holding
|
44.72 % | 66.26 % | 51.83 % |
Share Pledged by Promoters
|
0.0 | 14.12 % | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-1.57 % | -4.22 % | -6.04 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.2 % | 3.84 % | 15.13 % |
Ipca Laboratories
|
Ajanta Pharma
|
Gland Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|